Article
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 May 2022
Heersche Niels, Veerman G D Marijn, de With Mirjam, Bins Sander, Assaraf Yehuda G, Dingemans Anne-Marie C, van Schaik Ron H N, Mathijssen Ron H J, Jansman Frank G A
Abstract excerpt
Small-molecule kinase inhibitors (SMKIs) represent the cornerstone in the treatment of non-small cell lung cancer (NSCLC) patients harboring genetic driver mutations. Because of the introduction of SMKIs in the last decades, treatment outcomes have drastically improved. Their treatment efficacy, the development of drug resistance as well as untoward toxicity, all suffer from large patient variability. This...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.